Overall, the XPF-rs1799801 polymorphism was not significantly associated with cancer risk (homozygous model: OR = 0.91, 95% CI = 0.79–1.04, P = 0.783 for heterogeneity test, I2 = 0; recessive model: OR = 0.89, 95% CI = 0.78–1.01, P = 0.764 for heterogeneity test, I2 = 0; Table 2). This evidence concerns the gene ERCC4 and cancer.